Anti-Nicotinic Acetylcholine Receptor beta antibody [B3] (ab11150)


  • Product nameAnti-Nicotinic Acetylcholine Receptor beta antibody [B3]
    See all Nicotinic Acetylcholine Receptor beta primary antibodies
  • Description
    Mouse monoclonal [B3] to Nicotinic Acetylcholine Receptor beta
  • SpecificityAb11150 binds human AChR Beta subunit. Exhibits homogenous, high avidity binding to the receptor. Binding to recombinant beta subunit demonstrated on Western blotting.
  • Tested applicationsSuitable for: Flow Cyt, IHC-Fr, WB, IPmore details
  • Species reactivity
    Reacts with: Human
    Does not react with: Mouse, Rat, Chicken
  • Immunogen

    Full length protein (Human).


  • FormLiquid
  • Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.
  • Storage bufferPreservative: 0.09% Sodium Azide
    Constituents: PBS
  • Concentration information loading...
  • PurityProtein G purified
  • ClonalityMonoclonal
  • Clone numberB3
  • MyelomaNS1
  • IsotypeIgG1
  • Research areas


Our Abpromise guarantee covers the use of ab11150 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
Flow Cyt 1/1. ab170190-Mouse monoclonal IgG1, is suitable for use as an isotype control with this antibody.
IHC-Fr 1/3.
WB 1/100. Predicted molecular weight: 60.1 kDa.
IP 1/100.


  • FunctionAfter binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
  • Involvement in diseaseDefects in CHRNB1 are a cause of congenital myasthenic syndrome slow-channel type (SCCMS) [MIM:601462]. SCCMS is the most common congenital myasthenic syndrome. Congenital myasthenic syndromes are characterized by muscle weakness affecting the axial and limb muscles (with hypotonia in early-onset forms), the ocular muscles (leading to ptosis and ophthalmoplegia), and the facial and bulbar musculature (affecting sucking and swallowing, and leading to dysphonia). The symptoms fluctuate and worsen with physical effort. SCCMS is caused by kinetic abnormalities of the AChR, resulting in prolonged endplate currents and prolonged AChR channel opening episodes.
    Defects in CHRNB1 are a cause of congenital myasthenic syndrome with acetylcholine receptor deficiency (ACHRDCMS) [MIM:608931]. ACHRDCMS is a post-synaptic congenital myasthenic syndrome. Mutations underlying AChR deficiency cause a 'loss of function' and show recessive inheritance.
  • Sequence similaritiesBelongs to the ligand-gated ion channel (TC 1.A.9) family. Acetylcholine receptor (TC 1.A.9.1) subfamily. Beta-1/CHRNB1 sub-subfamily.
  • Cellular localizationCell junction > synapse > postsynaptic cell membrane. Cell membrane.
  • Information by UniProt
  • Database links
  • Alternative names
    • Acetylcholine receptor protein beta chain precursor antibody
    • Acetylcholine receptor subunit beta antibody
    • ACHB_HUMAN antibody
    • AChR antibody
    • ACHRB antibody
    • Cholinergic receptor nicotinic beta polypeptide 1 (muscle) antibody
    • Chrnb 1 antibody
    • CHRNB antibody
    • chrnb1 antibody
    • CMS1D antibody
    • CMS2A antibody
    • Nicotinic acetylcholine receptor beta subunit precursor antibody
    • SCCMS antibody
    see all

References for Anti-Nicotinic Acetylcholine Receptor beta antibody [B3] (ab11150)

ab11150 has not yet been referenced specifically in any publications.

Product Wall

There are currently no Abreviews or Questions for ab11150.
Please use the links above to contact us or submit feedback about this product.